Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.

作者信息

Peest D, Deicher H, Coldewey R, von Broen I M, Cammerer U, Hein R, Hoffmann L, Konyar H, Kreuser E D, Selbach J

机构信息

Abt. Immunologie und Transfusionsmedizin, Zentrum Innere Medizin und Dermatologie, Med. Hochschule Hannover, FRG.

出版信息

Onkologie. 1990 Feb;13(1):43-4. doi: 10.1159/000216718.

136 untreated multiple myeloma patients of stage II and III were collected in the study. 37/51 stage II patients had progressive disease and were treated with melphalan and prednisone (MP). 85 patients were of stage III and randomized into MP and vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) treatment groups. 55% of MP treated patients responded versus 75% of the VBAMDex group. Since the study has been activated only 16 months ago, no difference in survival could be observed.